Market Currents
BioLineRx (BLRX +5.9%) trades higher after saying it's completed pre-clinical development of its...
-
Tuesday, October 16, 2012, 1:31 PM ETBioLineRx (BLRX +5.9%) trades higher after saying it's completed pre-clinical development of its BL-8020 drug candidate, an oral treatment for Hepatitis C. The company plans to initiate a Phase I/II safety and efficacy study in Europe starting early next year and is expecting to receive regulatory approvals from the appropriate authorities by year's end.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
